GlassScriptPhysician profile
Beth G Goldstein
NPI 1073594412
$1,928.97
in general payments reported to CMS, 2019-2025
25 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $115 · 2021: $252 · 2022: $669 · 2023: $413 · 2024: $141 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.42 | 2022-2025 | |
| Abbvie INC. | $231.99 | 2019-2024 | |
| Genzyme Corporation | $163.89 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $156.14 | 2022-2023 | Dupixent |
| Vector Surgical, LLC | $150.00 | 2021 | |
| Janssen Biotech, INC. | $142.25 | 2019-2025 | Simponi, Remicade, Stelara |
| Leo Pharma INC. | $117.52 | 2020-2023 | Adbry |
| Organogenesis INC. | $106.04 | 2023-2024 | Puraply, Apligraf |
| Allergan, INC. | $74.89 | 2020-2021 | |
| Pfizer INC. | $65.94 | 2019-2020 | |
| Organon LLC | $62.22 | 2025 | Vtama |
| Dermavant Sciences, INC. | $45.99 | 2022-2024 | Vtama |
| Revance Therapeutics, INC. | $40.76 | 2025 | Daxxify |
| Convatec INC. | $40.66 | 2023 | |
| Sun Pharmaceutical Industries INC. | $38.22 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35.79 | 2019 | |
| Dusa Pharmaceuticals, INC. | $32.74 | 2019 | |
| Arcutis Biotherapeutics, INC. | $31.26 | 2023-2025 | Zoryve |
| Biofrontera INC. | $29.69 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $24.28 | 2022 | |
| Ucb, INC. | $21.33 | 2022 | |
| Amgen INC. | $19.67 | 2021 | |
| Mission Pharmacal Company | $19.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.06 | 2023 | Sotyktu |
| Sensus Healthcare, INC. | $8.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.